H.C. Wainwright lowered the firm’s price target on MacroGenics (MGNX) to $2 from $4 and keeps a Neutral rating on the shares. The firm says it has been a long time coming for discontinuing clinical development of vobra duo.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue